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Teaser: Assessing targets for safety in drug discovery is central to de-risking drug projects 
early, reducing failure and creating an environment for successful progression to clinical 
trials.  
 
  
Abstract: 
 
How can small to medium-sized pharma and biotech companies enhance the chances of 
running a successful drug project and maximise the return on a limited number of assets? 
 
Having a full appreciation of the safety risks associated with proposed drug targets is a 
critical element in understanding the unwanted side-effects that might stop a project in its 
tracks.  Having this information is necessary to complement knowledge about the likely 
efficacy of a future drug. However, the lack of data-rich insight into drug target safety is one 
of the major causes of drug project failure today.  
 
Conducting comprehensive target safety reviews early in the drug discovery process enables 
drug project teams to make the right decisions about which drug targets to take forward.  
 
 
 
Understanding the unwanted effects of engaging a potential target is a piece of news that – 
seemingly – some pharma companies don’t want to read. And yet, target-related safety 
issues are responsible for many drug project failures.  
 
Around 10 years ago, large pharmaceutical companies started a process of self-analysis for 
project failures, looking particularly at safety and toxicology in discovery and early drug 
development. They established the two major safety reasons for project failure: 
  
1. Chemistry-related reasons: in other words, the drug itself would have unwanted side 
effects. 
2. Target reasons: there could be unwanted consequences of interacting with a particular 
target. 
  
As a result, large pharma recognised that a systematic, early review of potential safety 
issues associated with a drug target made sense [1]; implementation of this strategy has 
since reduced rates of project loss substantially [2-4].  
 
However, among medium and smaller-sized pharma companies – where it can be argued 
there is less experience than their larger counterparts – the focus of attention is on the 
potential efficacy of hitting a drug target and less on safety aspects. This can lead to a lack of 
consideration of the unintended consequences of working with a specific drug target.  
 
Aside from what might be a lack of knowledge at the smaller end of the pharma sector, 
there is also a fear factor based on the way they’re funded. Many biotech and small 
companies are largely reliant on venture capital funding and, to retain their commercial 
attractiveness to investors, they may be reluctant to generate data and information about a 
drug target that would expose its poor investment potential.  
 
This is not necessarily a deliberate move to mislead but a genuine desire to focus on 
generating positive data to reassure and persuade everyone involved in the project that 
hitting this target is a great idea and is important to addressing a particular disease. Smaller 
companies are often constrained because they are focusing on a relatively small number of 
targets and are trying to maximise the choices available to them, where larger companies 
have the option to review a greater number and choose the targets with the fewest risks.  
 
Where the reliance on enthusiasm and passion over facts and data can fall down is where 
investors back a project but then, further down the line, discover the toxicology data have 
killed the project which will, therefore, never deliver a financial return (Figure 1). Surely it’s 
better to present investors with a full picture – including any issues – early on in a project 
which will allow all concerned to continue moving forward, either with a different drug 
target or with full knowledge of the risks involved.  
 
Of course, this is preferable to reaching the point where you’re ready to dose the first 
human volunteers – which is governed by various regulatory guidelines – and the toxicology 
package delivers bad news. By that point, it’s too late to change direction. However, acting 
earlier in the project by taking a closer look at a target means you have more chance to 
mitigate the risks, perhaps by assessing whether the toxicity identified in animal studies is 
relevant to humans.  
 
Some companies will treat the toxicology element of drug development as a box-ticking 
exercise to complete before initiating clinical trials. However, they should understand that 
early assessment of risks provides a cost-effective way of identifying whether what they’ve 
got is really a good idea or not. 
 
That’s why, in assessing a potential drug target, there really is no such thing as bad news: 
the information you gain before investing seriously in a target helps companies to prioritise 
and conclude whether a particular target is a good idea and, if not, move their resources 
elsewhere (Figure 2). It’s far better to know this upfront than to go forward into toxicology 
studies with issues that will affect the long-term viability of the project.  
 
Target safety assessments: addressing drug target issues early in drug discovery 
 
For almost all drug projects it’s normal to come forward with a well-characterised view of 
the function of individual protein molecules and the efficacy of the drug target. However, 
what you rarely see is a characterisation of the risks associated with the specific drug target.  
Drug discovery has a tendency to concentrate on the disease biology and pursue a target 
without stopping to think of the unintended consequences.  
 
What is the approach and the output of a target safety assessment (Table 1)? 
 
1. Assessing risk 
Undertaking a target safety assessment early in the process allows you to create a table of 
risks and an understanding of how likely it is that each risk will occur, what is the probable 
impact of the risk and devising an integrated risk assessment plan. 
 
2. Summarising the target biology 
The background information you need to collate and summarise includes the target biology, 
listing alternative names, paralogs, homology in common preclinical species compared to 
humans. You also need the distribution and expression information in both humans and pre-
clinical species where possible; this means identifying which tissues contain the target and 
how prevalent they are in humans and other species so you can extrapolate between the 
two.  This is important in understanding both the relevance of preclinical safety species 
choices and in the likelihood of translation of preclinical observations to the clinic. 
 
3. Effects of loss or gain of function  within human and mouse phenotypes 
Looking at human and transgenic mouse phenotypes is about understanding what effect the 
target has on the tissue of interest. For example, what would happen by inhibiting target X? 
This involves reviewing transgenic mouse phenotypes to see what effects modifying the 
target has on model species and also the human genetic database for known mutations or 
familiar lines where a gene is mutated.  Overall, this helps to understand what effect 
inhibiting a target might have on humans.   If the intention is to activate the target then 
data from in vitro/in vivo gene knock-in experiments could also be valuable.   In weighing up 
the overall risk, it’s key to take into account the strengths and limitations of these different 
data sources.  It’s quite an extrapolation from gene knock-out in a transgenic mouse to 
partial or transient inhibition of a target in humans.   
 
4. Identifying safety risks by organ system 
A target safety assessment also tests the potential safety risks by organ system including 
bone, cardiovascular, endocrine, gastrointestinal, hematopoietic, immune, kidney, liver, 
muscle, nervous, reproductive, respiratory, skin and special senses.  
 
5. Competitor compound information 
Reviewing competitor compound information reveals whether any previous drug used to 
inhibit the target or a related pathway resulted in toxicity. This gives you important insight 
into what might happen in animals or in people with your chosen target – useful 
information to have while the project still has choices and hasn’t invested too much money.  
The availability and value of pre-clinical and clinical data can vary considerably – if a 
compound has stopped before registration it may be hard to find data.  However, if a drug is 
registered then extensive preclinical and clinical data may be readily available. 
 
6. Other considerations such as modality and target patient population 
Knowledge of the intended modality (such as small molecules, antibodies or 
oligonucleotides) can influence risk.  For example, an antibody approach could be used for a 
target present at the cell membrane without necessarily triggering activation/inhibition of 
the intracellular target.   Similarly, the risk profile may support inhibiting or activating a drug 
target in certain diseases and patient groups but not in others.    
 
 
Target safety assessment – understanding the risk-benefit ratio 
 
Conducting target safety assessments early in the drug discovery process means a company 
might conclude that it has a suitable target to start developing a drug while, equally, 
pinpointing relevant risks. The project can then assess whether those risks have manifested 
themselves in the pre-clinical animal studies and are real risks or not.  
 
The target safety assessment should grow with the project and become a comprehensive 
document. This is extremely valuable because, as the project progresses, you are trying to 
understand the risk-benefit ratio: what is the likely benefit to patients and are the risks 
acceptable to this patient population? 
  
Having a live assessment document means you can call upon it at different stages and 
answer questions including: “did the risk identified in the in-silico research manifest itself? 
How severe was it?” If the risk didn’t manifest itself, it may be downgraded in terms of what 
is monitored in the clinic.   
 
For example, if the target safety assessment highlighted a potential risk is bone marrow, you 
could take bone marrow from early efficacy or toxicology studies in animals and see if the 
predictions were correct and build them into the overall target assessment. This allows the 
project team to have data-driven, risk-benefit assessment at all times. And, it could start to 
inform the clinical trial monitoring and identify exclusions for certain patient groups. This is 
about taking the long view, looking ahead to creating the environment for a successful 
clinical programme by being aware of the risks and mitigating them where possible.  
 
 
 
Target safety reviews: de-risking projects early 
 
In his chapter for Drug Safety and Evaluation – Methods and Protocols, Richard J. Brennan 
says: 
  
Modern approaches to drug discovery and development increasingly demand a 
comprehensive understanding of the biological functions of the proposed target and its 
relationship to the projected indications. From the perspective of the project team 
toxicologist, understanding target function must go beyond “normal” biology and disease 
relationship and take into account possible unintended adverse consequences of target 
engagement by whatever modality is chosen [1].  
 
He also states that ‘The goal of a target safety evaluation is to identify potential unintended 
consequences of target modulation and to propose a risk evaluation and mitigation strategy 
to shepherd compounds through the discovery and development pipeline, to confirm and 
characterize unavoidable on-target toxicities in a timely manner to assist in early program 
advancement decisions and to anticipate, monitor and manage potential clinical adverse 
events [5]. 
 
In addition, the summary of a joint workshop held by the Academy of Medical Sciences and 
the Association of the British Pharmaceutical Industry reported:  
 
Robust target identification and validation is critical to ensuring that the right target is 
selected –and helping to ‘de-risk’ the R&D process…overall, improving the quality of targets 
and subsequent compounds entering clinical development, and developing robust 
biomarkers in parallel for ‘go’ or ‘no go’ decisions, offers efficiency gains in R&D by reducing 
the number of failures seen in clinical trials [6].  
 
Conclusion: Taking the right risk in drug discovery and development 
 
It is acceptable in drug discovery and development to take risks but companies need to 
ensure they have all the necessary information to take the right risks. 
  
Smaller and medium-sized pharma companies don’t have the luxury to take the wrong risk. 
With resources only for one or two targets it’s vital to make the right choice. Therefore, 
decisions should be made based on having all the information. A target assessment is a vital 
part of that.  
 
Having a passionate target or project champion who is convinced that a particular drug 
target is the right way to go is laudable. However, it also needs a member of the project 
team – perhaps the one responsible for funding the project – to provide a check and 
balance on decisions driven by enthusiasm alone.  
 
Drug discovery is difficult and it’s important to have people guided by passion and a belief 
that what they’re doing can make a difference to patients. However, it also needs a more 
rational view to counterbalance, with people who are willing to ask the difficult questions 
early and be willing to listen to the answers.  
 
Biology provides us with clues to what might happen to humans with certain targets, 
therefore target safety assessments are essential to help those in drug discovery and 
development to take the right risk.  
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Figure legends 
 
FIGURE 1 
 
A schematic depicting drug project value.  A drug project increases in value as it progresses 
through candidate selection towards first time in man (FTIM) and towards proof of concept 
(POC) in the clinic.  Inflection points reflect key decisions points where positive data cause a 
step up in value.   The orange line depicts a project where careful rerisking drives a more 
rapid increase in value compared with a project where risks are not adequately evaluated 
(red line).  The emergence of unexpected, unfavourable data can cause project failure due 
to toxicological risks that could have been identified and mitigated earlier in discovery and 
development.   
 
FIGURE 2 
 
The role of target safety assessments in drug discovery and development.  How well do we 
understand the role of the intended drug target in normal physiology and the toxicological 
consequences of its modulation?  Expert assessment and interpretation literature and 
available databases is invaluable in identifying and mitigating target-related risk.  
 
 
 
 
 
 
 
